TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03808220

Intervention type: BEHAVIORAL
Intervention: postoperative pain intensity
Description: estimate the postoperative pain intensity by using a scaling system via questionnaire

Intervention type: BEHAVIORAL
Intervention: postoperative pain intensity
Description: estimate the postoperative pain intensity by using a scaling system via questionnaire

Intervention type: BEHAVIORAL
Intervention: preoperative pain frequency
Description: estimate the preoperative pain intensity by using a scaling system via questionnaire

Intervention type: BEHAVIORAL
Intervention: preoperative pain frequency
Description: estimate the preoperative pain intensity by using a scaling system via questionnaire

Intervention type: BEHAVIORAL
Intervention: Side effect
Description: investigate the presence of any side effect
Study: NCT02921997

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent influenza A/H7N9 virus vaccine
Description: Monovalent influenza A/H7N9 virus vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent influenza A/H7N9 virus vaccine
Description: Monovalent influenza A/H7N9 virus vaccine.
Study: NCT04266093

Intervention type: DRUG
Intervention: GeneTherapy
Description: Observation/ Gene Therapy Long-term Follow-up. Subjects who have received treatment on an applicable NCI CIO gene therapy protocol.
Study: NCT01608802

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Palliative care
Description: Regular appointments with an existing clinic nurse who has been trained in palliative care, the patient is asked about their physical, psychological, social and spiritual problems, and a care management plan devised with referral as necessary.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Patients attend monthly for their ART monitoring and prescription filling, and a multiprofessional team is available as necessary.
Study: NCT02869347

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conestat alfa
Description: Two intravenous injections (over 5 minutes) of Conestat alfa immediately pre-procedure (elective coronary angiography) and 4 hours later; for patients less than 84kg at a dose of 50 U/kg, and for patients of 84kg body weight or greater at a dose of 4200 U.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride 0.9%
Description: Two intravenous injections of sodium chloride 0.9% (maximum 28 ml, matching the respective amount of the Conestat alfa arm) immediately pre-procedure (elective coronary angiography) and 4 hours later.
Study: NCT00593723

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Study: NCT02825017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coppertone (BAY 987517)
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2mg/cm\*2 test application.(Formulation-SR15-79_Y73-161)
Study: NCT03074825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chiauranib
Description: Take 50mg orally once daily
Study: NCT03925948

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PLAN 4 Success-Diabetes
Description: The study intervention-PLAN 4 Success-Diabetes-consisted of four 1 to 1 ½-hour weekly health literacy training and disease knowledge education sessions for four weeks (4 in-person sessions), followed by two home visits and monthly phone counseling for over 6 months (5 phone sessions). The intervention is theory-driven and builds on von Wagner's model to incorporate key elements such as health literacy, disease knowledge, and self-efficacy for better glucose outcomes.
Study: NCT03547375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib 500mg/d po,28 days as one cycle
Study: NCT04327414

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: Standing desks
Study: NCT04111874

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Teletherapy LTA
Description: Participating families will receive a copy of the book 'Helping Your Anxious Child, 2nd Edition', as well as the companion parent and child workbooks, to use at home and in session with the therapist. During each of the four videoconferencing sessions, therapists will serve to provide encouragement and support as the parent works through the program independently.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Teletherapy STA
Description: Participating families will also receive a copy of the book 'Helping Your Anxious Child, 2nd Edition', as well as the companion parent and child workbooks, to use at home and in session with the therapist. During each of the ten videoconferencing sessions, therapists will guide the parent through the implementation of the program, including explaining materials, assisting to develop planned therapy activities with the child, and problem-solving as needed.
Study: NCT04116398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone with 2 loading doses followed by PRN regimen.
Description: * Loading dose with 2 systematic intravitreal injections (IVI) of ozurdex at the baseline and 12 weeks.Followed by a PRN regimen with strict retreatment criteria (already used and published in the Prediamex study, Bellocq,Kodjikian et al Ophthalmology Retina 2017)~* Retreatment criteria: Reduction in VA ≥ 5 ETDRS Letters; and/or CSMT ≥ 275 microns by OCT-Cirrus® or ≥ 285 microns by OCT Spectralis®/Topcon; and/or increase of CSMT \> 50 microns; and/or onset of recurrent retinal cysts; and/or residual edema considered by the practitioner to be clinically significant.~* Minimal time limit between two IVI : 12 weeks~* Visits: monthly during 1 year (to check efficacy and safety) and then for the 2nd-year only at Month18 (M18) and Month 24 (M24)
Study: NCT02107521

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intracytoplasmic morphologically selected sperm injection
Description: Sperm selection for injection will be performed at 6600x magnification
Study: NCT03526861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tralokinumab
Description: Tralokinumab is a human recombinant monoclonal antibody of the immunoglobulin G4 (IgG4) subclass that specifically binds to human interleukin (IL) 13 and blocks interaction with the IL-13 receptors.
Study: NCT03808220

Intervention type: BEHAVIORAL
Intervention: Side effect
Description: investigate the presence of any side effect
Study: NCT03526861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tralokinumab
Description: Tralokinumab is a human recombinant monoclonal antibody of the immunoglobulin G4 (IgG4) subclass that specifically binds to human interleukin (IL) 13 and blocks interaction with the IL-13 receptors.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tralokinumab
Description: Tralokinumab is a human recombinant monoclonal antibody of the immunoglobulin G4 (IgG4) subclass that specifically binds to human interleukin (IL) 13 and blocks interaction with the IL-13 receptors.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tralokinumab
Description: Tralokinumab is a human recombinant monoclonal antibody of the immunoglobulin G4 (IgG4) subclass that specifically binds to human interleukin (IL) 13 and blocks interaction with the IL-13 receptors.
Study: NCT02107521

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intracytoplasmic sperm injection
Description: sperm selection for injection will be performed under 400x magnification
Study: NCT01634698

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: retinyl palmitate (UNICEF, Melbourne, Australia)
Description: the patients received an oral dose of 1500 IU or 2500 IU, once.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: retinyl palmitate (UNICEF, Melbourne, Australia)
Description: the patients received an oral dose of 1500 IU or 2500 IU, once.
Study: NCT04241250

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EAW+SCES (exoskelton and spinal cord epidural stimulation)
Description: Three months of exoskeleton training followed by 6 months of epidural stimulation.
Study: NCT03526861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tralokinumab
Description: Tralokinumab is a human recombinant monoclonal antibody of the immunoglobulin G4 (IgG4) subclass that specifically binds to human interleukin (IL) 13 and blocks interaction with the IL-13 receptors.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tralokinumab
Description: Tralokinumab is a human recombinant monoclonal antibody of the immunoglobulin G4 (IgG4) subclass that specifically binds to human interleukin (IL) 13 and blocks interaction with the IL-13 receptors.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tralokinumab
Description: Tralokinumab is a human recombinant monoclonal antibody of the immunoglobulin G4 (IgG4) subclass that specifically binds to human interleukin (IL) 13 and blocks interaction with the IL-13 receptors.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: Placebo contains the same excipients in the same concentration only lacking tralokinumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: Placebo contains the same excipients in the same concentration only lacking tralokinumab.
Study: NCT04146792

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: body acceptance program
Description: Complete 3 writing exercises over the course of week. Each writing exercise will take approximately 15 minutes to complete

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: writing creatively program
Description: Complete 3 writing exercises over the course of week. Each writing exercise will take approximately 15 minutes to complete
Study: NCT00901550

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: All participants received oral Methotrexate(MTX), starting at 7.5 mg/week. In patients with persistent tender or swollen joints, the dose was escalated in a graduated manner (2.5 mg/week every 1-2 weeks) to 15 mg/week by week 4 or 20 mg/week by week 8

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab
Description: Patients in combination group receive infliximab 3mg/kg at weeks 0, 2, and 6 and every 8 week thereafter.
Study: NCT01169064

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Silver-containing surgical dressing
Description: Dressing placed over surgical incision and remain for 3-5 days

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cloth adhesive dressing
Description: Cloth adhesive dressing placed over surgical incision and remains for 3-5 days
Study: NCT03638804

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 89Zr-KN035
Description: Single injection of 89Zr labeled KN035 in subjects to observe KN035 affinity in PD-L1 expressed Solid tumors by using PET imaging.
Study: NCT03856125

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PENS plus exercise
Description: The technique will be performed ultrasound-guided on the radial nerve, the places of the needle's insertions will be the following:~* Needle will be placed at under the lateral intermuscular septum between the triceps brachii and brachialis, approximately 10cm superior to the lateral epicondyle~* Needle will be placed at the upper third of the forearm on the posterior interosseous nerve after passing the arcade of Froshe's~The percutaneous electrical stimulation will be realized with a transcutaneous electric nerve stimulation (TENS) current:~* TENS Frequency - 2 Hz~* TENS Pulse width - 250 microseconds~* Duration - 30 minutes.~* TENS Intensity - Increased at an intensity of visible motor response of the innervated musculature and maximal tolerable intensity.~* Administration - One per week

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham PENS plus exercise
Description: The technique will be performed on the radial nerve, the places of the needle's. The technique will be performed ultrasound-guided on the radial nerve, the places of the needle's insertions will be the following:~* Needle will be placed at under the lateral intermuscular septum between the triceps brachii and brachialis, approximately 10cm superior to the lateral epicondyle.~* Needle wil be placed at the at the upper third of the forearm on the posterior interosseous nerve after passing the arcade of Froshe's.~The current will not be working, and the needles will be placed during 30 minutes.~- Administration - One per week
Study: NCT04646265

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: periodontal treatment
Description: non-surgical root debridement
Study: NCT04663529

Intervention type: OTHER
Intervention: contact lens
Description: daily disposable soft contact lens
Study: NCT03550677

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: general anesthesia
Description: The patient will be monitored with ECG, pulse oximetry and noninvasive blood pressure. Anesthesia will be induced using 2-2.5 mg/kg propofol, 1-2 mcg/kg fentanyl, 10-20 mg rocuronium and proper size Laryngeal mask airway will be placed securely the airway.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: general anesthesia
Description: The patient will be monitored with ECG, pulse oximetry and noninvasive blood pressure. Anesthesia will be induced using 2-2.5 mg/kg propofol, 1-2 mcg/kg fentanyl, 10-20 mg rocuronium and proper size Laryngeal mask airway will be placed securely the airway.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ankle block
Description: ankle nerve block will be performed in group ankle block patients using a mixture of 5 ml of 2% lidocaine and 10 ml of 0.5% bupivacaine and same amount placebo (saline) in groups placebo under the guidance of peripheral nerve stimulator the anesthesia will be discontinued and LMA will be removed. The patients will be transferred from postoperative care unit to the ward after they are eligible for discharge according to modified Aldrete scoring system.
Study: NCT04643977

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mARG-01-17 (mesohyal AGRIBENONE)
Description: Dermal Filler
Study: NCT04931030

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary advice
Description: Subjects are provided dietary advice by the dietitians as part of the research team/ investigators
Study: NCT04276246

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dental implants and retentive implant components
Description: retentive components (Group A Test), which are connected to the implants to retain the RPD

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dental implants and supportive implant components
Description: supportive components (Group B Control), which are connected to the implants to support the RPD
Study: NCT00815932

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TDCS/sham procedure on five consecutive days
Description: The latency and amplitude of P300, subjective pain intensity, and pain thresholds for tactile and thermal stimuli will be determined at before and 15 min and 120 min after the 1st and 5th tDCS/sham procedure, To receive tDCS/sham treatment, two electrodes will be placed on the patient´s skull (for details see section Methods) and the patient will rest for 5 min. After that, the patient will receive 20 minutes of 2 mA tDCS/sham. Subjective pain intensity, and pain thresholds for tactile and thermal stimuli will be determined before-, 15 min after and 120 min after each tDCS/Sham procedure. At the 1st and 5th tDCS/Sham session, the latency and amplitude of P300 will be determined before-, 15 min after and 120 min after the tDCS/sham procedure.
Study: NCT03717610

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radical surgery with HIPEC
Description: Straight after macroscopic radical cytoreductive surgery, an intraperitoneal hyperthermic perfusion using the open-abdomen technique will be performed with a single dose of cisplatin 100 mg/m2 administered for 90 minutes in the hyperthermic phase (41°C-43°C).
Study: NCT04116346

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral intake allowed
Description: Oral intake (food and fluids) allowed up to the time of the procedure
Study: NCT03715595

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SSDM group
Description: The patients can perform self-evaluation, including DAS28, morning stiffness duration (MSD) and HAQ, and input medical records (including medication and laboratory test results) every month.
Study: NCT03974984

Intervention type: PROCEDURE
Intervention: Colon Resection
Description: All patients undergo laparoscopic colon cancer resection.

Intervention type: PROCEDURE
Intervention: Colon Resection
Description: All patients undergo laparoscopic colon cancer resection.

Intervention type: PROCEDURE
Intervention: Epidural anesthesia
Description: Epidural inserted preoperatively and kept for 1 day postoperatively

Intervention type: DRUG
Intervention: NSAID
Description: NSAID administered according to standard operating procedure postoperatively
Study: NCT02700802

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Feed1st
Description: Feed1st is a unique hospital-based hunger mitigation program that, since 2010, has operated low-cost, self-serve food pantries at Comer Children's Hospital. All parents and caregivers with a hospitalized child have 24/7 free access to these self-serve pantries with the option to eat food in the pantry, carry out as much food as needed, and contribute back to the pantry with food, volunteerism, or other resources. The program also offers free phone/text/email navigation for food support and other basic needs resources. We aim to conduct a 3-arm, randomized comparative effectiveness study to evaluate the impact, versus usual care, of two alternative referral strategies to increase Feed1st program utilization and impact.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Feed1st
Description: Feed1st is a unique hospital-based hunger mitigation program that, since 2010, has operated low-cost, self-serve food pantries at Comer Children's Hospital. All parents and caregivers with a hospitalized child have 24/7 free access to these self-serve pantries with the option to eat food in the pantry, carry out as much food as needed, and contribute back to the pantry with food, volunteerism, or other resources. The program also offers free phone/text/email navigation for food support and other basic needs resources. We aim to conduct a 3-arm, randomized comparative effectiveness study to evaluate the impact, versus usual care, of two alternative referral strategies to increase Feed1st program utilization and impact.
Study: NCT02649231

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: 0.8 mg/kg ketamine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: 0.8 mg/kg ketamine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 0.9% saline

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychological Therapy
Description: Manualised relapse prevention based CBT

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychological Therapy
Description: Manualised relapse prevention based CBT

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol Education
Description: Simple education about alcohol effects

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Alcohol Education
Description: Simple education about alcohol effects
Study: NCT03295799

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Self-Management
Description: Patient will manage their own warfarin therapy.
Study: NCT00815932

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TDCS/sham procedure on five consecutive days
Description: The latency and amplitude of P300, subjective pain intensity, and pain thresholds for tactile and thermal stimuli will be determined at before and 15 min and 120 min after the 1st and 5th tDCS/sham procedure, To receive tDCS/sham treatment, two electrodes will be placed on the patient´s skull (for details see section Methods) and the patient will rest for 5 min. After that, the patient will receive 20 minutes of 2 mA tDCS/sham. Subjective pain intensity, and pain thresholds for tactile and thermal stimuli will be determined before-, 15 min after and 120 min after each tDCS/Sham procedure. At the 1st and 5th tDCS/Sham session, the latency and amplitude of P300 will be determined before-, 15 min after and 120 min after the tDCS/sham procedure.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TDCS/sham procedure on five consecutive days
Description: The latency and amplitude of P300, subjective pain intensity, and pain thresholds for tactile and thermal stimuli will be determined at before and 15 min and 120 min after the 1st and 5th tDCS/sham procedure, To receive tDCS/sham treatment, two electrodes will be placed on the patient´s skull (for details see section Methods) and the patient will rest for 5 min. After that, the patient will receive 20 minutes of 2 mA tDCS/sham. Subjective pain intensity, and pain thresholds for tactile and thermal stimuli will be determined before-, 15 min after and 120 min after each tDCS/Sham procedure. At the 1st and 5th tDCS/Sham session, the latency and amplitude of P300 will be determined before-, 15 min after and 120 min after the tDCS/sham procedure.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TDCS/sham procedure on five consecutive days
Description: The latency and amplitude of P300, subjective pain intensity, and pain thresholds for tactile and thermal stimuli will be determined at before and 15 min and 120 min after the 1st and 5th tDCS/sham procedure, To receive tDCS/sham treatment, two electrodes will be placed on the patient´s skull (for details see section Methods) and the patient will rest for 5 min. After that, the patient will receive 20 minutes of 2 mA tDCS/sham. Subjective pain intensity, and pain thresholds for tactile and thermal stimuli will be determined before-, 15 min after and 120 min after each tDCS/Sham procedure. At the 1st and 5th tDCS/Sham session, the latency and amplitude of P300 will be determined before-, 15 min after and 120 min after the tDCS/sham procedure.
Study: NCT04022057

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Ropivacaine injection
Description: Local anesthetic injection
Study: NCT03111888

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silicone Stent Airway Implant
Description: The Patient-Specific Tracheobronchial Stent is a silicone stent indicated for use in adults that have stenosis of the airway. The subject device takes a CT scan, thresholds out the airway from the other anatomy, and allows the physician to digitally build the stent to his/her desired dimensions. According to the physician's design, a patient-specific stent can be manufactured using rapid prototyping technology. The patient-specific stent is indicated for use with any rigid bronchoscopy/stent application system that fits the design envelope.